Recognizing the vital role played by research and development in overall operations as well as in future progress of the company, julphar assigns great emphasis to this function.

Julphar is continuously involved in the development of ways and means to explore new application of the generic dosage forms and support and participate by way of providing heavy grants to research organizations and universities of international repute which are working for development and discovery of new molecules.

the management of Julphar is ready to explore new ideas in the flied of pharmaceutical technology and strongly believe in managing research & Development department of world class standard. the R & D laboratory of Julphar is equipped with state-of-the-art product development and testing instruments and it was found up to the market when inspected by FDA consultants and other world renowned regulatory bodies.

One of the important functions of R&D Department is to carry out bioequivalence studies for Julphar products in conjunction with Drug  Information Department. when results of these studies show that Julphar medicines, the general practitioner/ specialist feels free to prescribe Julphar products without any hesitation.

The product stability studies, safety and efficacy are ensured by using controlled stability simulator and in-vitro bio-studies in Product Development Laboratory prior to detailed bio-equivalence studies. the laboratory system is based on cGMP, GLP, ICH, and FDA guidelines with ISO 9001 Certification. more than 25 scientists including MOH approved pharmacists are involved in the development of new products and have resulted in the registration of over 600 dosage forms worldwide.

With a view to get patented products of Julphar registered in USA, for he purpose of marketing, the Research & Development Department applied to US Patent Authority and succeeded in obtaining their approval in respect of quite many Julphar products. the recent approval from the US FDA has given a fillip to our efforts to penetrate in the US generic market.